Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US

AstraZeneca plc (NASDAQ:AZN) announced on Tuesday that it will invest $50 billion in the United States by 2030.

The investment will create new, highly skilled direct and indirect jobs nationwide, the company said.

The cornerstone of this landmark investment is a new multi-billion-dollar U.S. manufacturing facility that will produce drug substances for the company's weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9, and combination small-molecule products.

The new centre will produce small molecules, peptides, and oligonucleotides.

This multi-billion dollar capital investment is in addition to the $3.5 billion announced in November 2024.

The drug substance facility, planned for the Commonwealth of Virginia, would be AstraZeneca's largest single manufacturing investment in the world. It will leverage AI, automation, and data analytics to optimize production.

What Does The Investment Include?

The $50 billion investment across R&D and manufacturing footprint in the U.S. over the next five years also includes:

Expansion of R&D facility in Gaithersburg, Maryland

R&D centre in Kendall Square, Cambridge, Massachusetts

Manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, ...